LuMind IDSC Statement re: Donanemab Phase 3 Results
Pharmaceutical company Eli Lilly today announced results of a phase III clinical trial that proves their anti-amyloid drug, donanemab, significantly
May 3, 2023
Pharmaceutical company Eli Lilly today announced results of a phase III clinical trial that proves their anti-amyloid drug, donanemab, significantly
This study aimed to explore the natural history of morbidities throughout the lifespan of people with Down syndrome compared with other
Each year, the Down syndrome community and our supporters – family, friends, businesses, organizations and others – honor our loved
Parent, advocate, and published author, Steve Friedman has used his family’s recent experiences to help guide others. With The Essential
“Alzheimer’s meds are here. But for the Down syndrome community, it’s still the 1980s” by Annalee Armstrong, Fierce Biotech An
2/22/2023 (Burlington, MA) – Today the LuMind IDSC Foundation, a leading national Down syndrome research organization, announced a new collaboration
On Friday, January 6, the U.S. Food & Drug Administration (FDA) granted accelerated approval for lecanemab, an anti-amyloid drug to
Question: My son is 59 years old and was diagnosed with Alzheimer’s probably in March 2019. Other than that he
At an Alzheimer’s disease research conference last week, new clinical trial data was presented for an antibody drug candidate called
Eisai, a Japanese pharmaceutical company, and its partner Biogen, a Massachusetts-based biotechnology company, recently announced positive “topline” results from the